medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-9-76-81medsovet-1107Research ArticleОРГАНОПРОТЕКЦИЯ ПРИ ССПРезистентность к ацетилсалициловой кислоте: значение лекарственной формыAcetylsalicylic acid resistance: relevance of correct dosage formВоробьеваН. М.VorobyovaN. M.noemail@neicon.ruФГБУ «Российский кардиологический научно-производственный комплекс» Минздрава РоссииRussian Federation201330122013097681Copyright © Воробьева Н.М., 20132013Воробьева Н.М.Vorobyova N.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1107

Ацетилсалициловая кислота (АСК) – известный антитромботический препарат с более чем 100-летним опытом применения в медицине. Эффективность низких доз АСК (75–150 мг/сут) для вторичной профилактики сердечно-сосудистых заболеваний доказана в многочисленных исследованиях [1, 2]. Вместе с тем исследования показали, что терапия АСК предупреждает только 25% неблагоприятных сердечно-сосудистых событий [3–5].

Acetylsalicylic acid (ASA) is a well-known anti-thrombotic agent which has been used in medical practice for more than 100 years. The effectiveness of low-dose ASA (75-150 mg/day) in secondary prevention of cardiovascular disease is proved by numerous studies [1, 2]. At the same time, research revealed that aspirin therapy prevents only 25% of adverse cardiovascular events [3-5].

acetylsalicylic acidcardiovascular diseasesantithrombotic actionацетилсалициловая кислотасердечно-сосудистые заболеванияантитромботическое действиеReferencesAntithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // Br. Med. J. 2002. №324. Р. 71–86.Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // Br. Med. J. 2002. №324. Р. 71–86.Baigent C., Blackwell L., Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials // Lancet. 2009. №373. Р. 1849–1860.Baigent C., Blackwell L., Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials // Lancet. 2009. №373. Р. 1849–1860.Hankey G.J., Eikelboom J.W. Aspirin resistance // Lancet. 2006. №367. Р. 606–617.Hankey G.J., Eikelboom J.W. Aspirin resistance // Lancet. 2006. №367. Р. 606–617.Patrono C., Rocca B. Drug insight: aspirin resistance – fact or fashion? // Nat. Clin. Pract. Cardiovasc. Med. 2007. №4. Р. 42–50.Patrono C., Rocca B. Drug insight: aspirin resistance – fact or fashion? // Nat. Clin. Pract. Cardiovasc. Med. 2007. №4. Р. 42–50.Undas A., Brummel-Ziedins K.E., Mann K.G. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions // Blood. 2007. №109. Р. 2285–2292.Undas A., Brummel-Ziedins K.E., Mann K.G. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions // Blood. 2007. №109. Р. 2285–2292.Gum P.A., Kottke-Marchant K., Poggio E.D. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease // Am. J. Cardiol. 2001. №88. Р. 230–235.Gum P.A., Kottke-Marchant K., Poggio E.D. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease // Am. J. Cardiol. 2001. №88. Р. 230–235.Eikelboom J.W., Hankey G.J. Aspirin resistance: a new independent predictor of vascular events? // J. Am. Coll. Cardiol. 2003. №41. Р. 966–968.Eikelboom J.W., Hankey G.J. Aspirin resistance: a new independent predictor of vascular events? // J. Am. Coll. Cardiol. 2003. №41. Р. 966–968.Gum P.A., Kottke-Marchant K., Welsh P.A. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease // J. Am. Coll. Cardiol. 2003. №41. Р. 961–965.Gum P.A., Kottke-Marchant K., Welsh P.A. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease // J. Am. Coll. Cardiol. 2003. №41. Р. 961–965.DiChiara J., Bliden K.P., Tantry U.S. et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study // Diabetes. 2007. №56. Р. 3014–3019.DiChiara J., Bliden K.P., Tantry U.S. et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study // Diabetes. 2007. №56. Р. 3014–3019.Neubauer H., Kaiser A.F., Endres H.G. et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance–the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy // BMC. Med. 2011. №9. Р. 3.Neubauer H., Kaiser A.F., Endres H.G. et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance–the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy // BMC. Med. 2011. №9. Р. 3.Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy // Nature Rev. 2003. №2. Р. 15–28.Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy // Nature Rev. 2003. №2. Р. 15–28.Michelson A.D., Cattaneo M., Eikelboom J.W. et al. Aspirin Resistance: position paper of the Working Group on Aspirin Resistance // J. Thromb. Haemost. 2005. №3. Р. 1309–1311.Michelson A.D., Cattaneo M., Eikelboom J.W. et al. Aspirin Resistance: position paper of the Working Group on Aspirin Resistance // J. Thromb. Haemost. 2005. №3. Р. 1309–1311.Krasopoulos G., Brister S.J., Beattie W.S. et al. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis // Br. Med. J. 2008. №336. Р. 195–198.Krasopoulos G., Brister S.J., Beattie W.S. et al. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis // Br. Med. J. 2008. №336. Р. 195–198.Sofi F., Marcucci R., Gori A.M. et al. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events – a meta-analysis // Int. J. Cardiol. 2008. №128. Р. 166–171.Sofi F., Marcucci R., Gori A.M. et al. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events – a meta-analysis // Int. J. Cardiol. 2008. №128. Р. 166–171.Панченко Е.П., Добровольский А.Б. Тромбозы в кардиологии. Механизмы развития и возможности терапии. М.: Спорт и культура, 1999.Панченко Е.П., Добровольский А.Б. Тромбозы в кардиологии. Механизмы развития и возможности терапии. М.: Спорт и культура, 1999.Grosser T., Fries S., Lawson J.A. et al. Drug resistance and pseudoresistance. An unintended consequence of enteric coating aspirin // Circulation. 2013. №127. Р. 377–385.Grosser T., Fries S., Lawson J.A. et al. Drug resistance and pseudoresistance. An unintended consequence of enteric coating aspirin // Circulation. 2013. №127. Р. 377–385.Pedersen A., FitzGerald G. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase // N. Engl. J. Med. 1984. №311. Р. 1206–1211.Pedersen A., FitzGerald G. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase // N. Engl. J. Med. 1984. №311. Р. 1206–1211.Patrono C., Coller B., Dalen J.E. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects // Chest. 2001. №119. Р. 39S–63S.Patrono C., Coller B., Dalen J.E. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects // Chest. 2001. №119. Р. 39S–63S.Sagar K.A., Smyth M.R. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography // J. Pharm. Biomed. Anal. 1999. №21. Р. 383–392.Sagar K.A., Smyth M.R. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography // J. Pharm. Biomed. Anal. 1999. №21. Р. 383–392.Cox D., Maree A.O., Dooley M. et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers // Stroke. 2006. №37. Р. 2153–2158.Cox D., Maree A.O., Dooley M. et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers // Stroke. 2006. №37. Р. 2153–2158.Patrono C., Ciabattoni G., Pugliese F. et al. Radioimmunoassay of serum thromboxane B2: A simple method of assessing pharmacologic effects on platelet function // Adv. Prostaglandin Thromboxane Res. 1980. №6. Р. 187–191.Patrono C., Ciabattoni G., Pugliese F. et al. Radioimmunoassay of serum thromboxane B2: A simple method of assessing pharmacologic effects on platelet function // Adv. Prostaglandin Thromboxane Res. 1980. №6. Р. 187–191.Peace A., McCall M., Tedesco T. et al. The role of weight and enteric coating on aspirin response in cardiovascular patients // J. Thromb. Haemost. 2010. №8. Р. 2323–2325.Peace A., McCall M., Tedesco T. et al. The role of weight and enteric coating on aspirin response in cardiovascular patients // J. Thromb. Haemost. 2010. №8. Р. 2323–2325.Maree A., Curtin R., Dooley M. et al. Platelet response to low dose enteric-coated aspirin in patients with stable cardiovascular disease // J. Am. Col. Cardiol. 2005. №46. Р. 1258–1263.Maree A., Curtin R., Dooley M. et al. Platelet response to low dose enteric-coated aspirin in patients with stable cardiovascular disease // J. Am. Col. Cardiol. 2005. №46. Р. 1258–1263.Яковенко Э.П., Краснолобова Л.П., Яковенко А.В. [и др.] Влияние препаратов ацетилсалициловой кислоты на морфофункциональное состояние слизистой оболочки желудка у кардиологических пациентов пожилого возраста // Сердце. 2013. №12 (3). С. 145–150.Яковенко Э.П., Краснолобова Л.П., Яковенко А.В. [и др.] Влияние препаратов ацетилсалициловой кислоты на морфофункциональное состояние слизистой оболочки желудка у кардиологических пациентов пожилого возраста // Сердце. 2013. №12 (3). С. 145–150.

The authors declare that there are no conflicts of interest present.